Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RNXT | US
-0.04
-4.82%
Healthcare
Biotechnology
30/06/2024
24/04/2026
0.86
0.91
0.93
0.86
RenovoRx Inc. a clinical-stage biopharmaceutical company focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos California.
View LessValue Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
46.0%1 month
56.5%3 months
69.5%6 months
81.9%-
-
2.59
-
-
-4.72
-
-
-11.39M
20.55M
20.55M
-
-
-
-
-155.12
2.30
0.49
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.22
Range1M
0.44
Range3M
0.53
Rel. volume
0.82
Price X volume
268.32K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Evaxion Biotech A/S | EVAX | Biotechnology | 4.03 | 22.48M | -5.18% | n/a | 837.11% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 6.4 | 20.46M | 4.40% | n/a | 14.63% |
| Enlivex Therapeutics Ltd | ENLV | Biotechnology | 0.8885 | 19.02M | -2.01% | n/a | 2.92% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.88 | 18.75M | -2.59% | n/a | 3.49% |
| PLUR | PLUR | Biotechnology | 3.345 | 18.30M | -2.76% | n/a | 30845.83% |
| DOMH | DOMH | Biotechnology | 2.89 | 18.14M | 0.00% | n/a | 7.66% |
| DarT Bioscience Inc | DARE | Biotechnology | 2.11 | 18.03M | -0.47% | 0.12 | 218.34% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.91 | 17.74M | 0.00% | n/a | 0.00% |
| ICU | ICU | Biotechnology | 4.13 | 17.31M | -2.59% | n/a | -45.50% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 5.47 | 16.65M | -2.67% | n/a | 10.72% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.72 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.59 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 69.48 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 20.55M | 3.66B | Emerging |